$191.90 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter
Brokerages expect Omnicell, Inc. (NASDAQ:OMCL) to announce $191.90 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omnicell’s earnings, with the highest sales estimate coming in at $192.19 million and the lowest estimate coming in at $191.60 million. Omnicell posted sales of $176.74 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.6%. The firm is expected to announce its next earnings report on Thursday, October 26th.
According to Zacks, analysts expect that Omnicell will report full year sales of $191.90 million for the current financial year, with estimates ranging from $728.80 million to $731.86 million. For the next year, analysts expect that the company will post sales of $813.22 million per share, with estimates ranging from $808.50 million to $818.55 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Omnicell.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The firm had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. Omnicell’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 earnings per share.
A number of equities research analysts have recently commented on the company. Craig Hallum increased their price objective on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Dougherty & Co increased their price objective on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, July 28th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reiterated a “hold” rating and set a $40.00 price objective on shares of Omnicell in a research report on Sunday, July 30th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $47.00 price objective on shares of Omnicell in a research report on Tuesday, July 25th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $49.00.
COPYRIGHT VIOLATION WARNING: “$191.90 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/13/191-90-million-in-sales-expected-for-omnicell-inc-omcl-this-quarter.html.
In related news, VP Peter J. Kuipers sold 18,054 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $50.31, for a total value of $908,296.74. Following the completion of the sale, the vice president now owns 44,236 shares in the company, valued at $2,225,513.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Randall A. Lipps sold 9,900 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the completion of the sale, the chairman now owns 208,982 shares of the company’s stock, valued at approximately $8,986,226. The disclosure for this sale can be found here. Insiders have sold 199,823 shares of company stock valued at $9,301,391 over the last 90 days. Corporate insiders own 3.77% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Omnicell during the first quarter worth approximately $125,000. LS Investment Advisors LLC boosted its position in shares of Omnicell by 136.3% in the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock worth $145,000 after buying an additional 2,060 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock worth $165,000 after buying an additional 120 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Omnicell during the first quarter worth approximately $170,000. Finally, Turner Investments LLC acquired a new position in shares of Omnicell during the second quarter worth approximately $181,000. Institutional investors and hedge funds own 96.35% of the company’s stock.
Omnicell (NASDAQ:OMCL) opened at 50.10 on Friday. The firm’s 50-day moving average price is $45.37 and its 200 day moving average price is $41.17. The stock’s market cap is $1.88 billion. Omnicell has a 52-week low of $30.35 and a 52-week high of $51.98.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.